About

About
The DS management team has both a strong background in developing drugs for the market and experience in building life science companies.

Pipeline

Pipeline
DS Biopharma have three novel assets in various stages of clinical development and intend to add more bioactive lipids to the current portfolio in the coming years.

Investors

Investors
To date, DS Biopharma have been funded privately.

Latest Press Releases

March 6, 2019
Published by Adelle McGourty at March 6, 2019
Categories

Clinical Study Shows Topical DS107 Prevents Disease Exacerbation in Atopic Dermatitis Patients

Dublin, Ireland, March 06 2019 – DS Biopharma (DS) today announced positive results from a new study where continued treatment with 5% DS107 cream not only […]
Do you like it?0
0 Read more
November 19, 2018
Published by Adelle McGourty at November 19, 2018
Categories

DS Biopharma announces DS107 patent grant in the US for the treatment of atopic dermatitis

Dublin, Ireland, November 19th 2018 – DS Biopharma (DS), a privately held clinical stage biopharmaceutical company specialising in the development of novel bioactive lipids, today announced […]
Do you like it?0
0 Read more

More Press Releases

Media coverage

November 19, 2019
Published by micadmin at November 19, 2019
Categories

Pipeline full with agents in various phases of development | Dermatology Times

The following article appeared in Dermatology Times on 19th November 2019: https://www.dermatologytimes.com/atopic-dermatitis/pipeline-full-agents-various-phases-development As dermatologists gain experience with newer atopic dermatitis medications, they’re getting glimpses of data […]
Do you like it?0
0 Read more

Join our mailing list

Connect with us

Contact us

t: +353 1 2933 590
e: info@dsbiopharma.com